This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

OX17

Orexo AB

Drug Names(s): OX17

Description: OX17 combines two well-known substances that inhibit acid secretion in the stomach with different time to onset of effect; a H2 receptor antagonist (famotidine) and a proton-pump inhibitor (omeprazole).

Deal Structure: Orexo and Novartis
In August 2009, Orexo signed a license agreement with Novartis in respect of OX17. Novartis is responsible for all continuing development costs. In February 2013, Novartis terminated its licence agreement with Orexo for OX17.


OX17 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug